NCI-Funded Clinical Research In Jeopardy, ASCO Focuses on Value of NCTN Groups

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login